PharmX Technologies (PHX) H2 2025 earnings summary

Executive summary

• FY25 revenue grew 13% year-over-year to AUD 7.53 million, driven by strong performance in both Gateway and Marketplace segments and supported by platform enhancements and new product launches.

• Gross margin improved by 1% to 82%, despite increased investments in people, technology, and development.

• Marketplace revenues tripled year-over-year, with significant increases in orders and processed invoice value.

• Cash position at year-end was AUD 4.2 million, with positive underlying operating cash flows.

• Expanded supplier network by 16% and active accounts, supporting increased order flow and revenue.

Financial highlights

• Revenue reached AUD 7.53 million, a 13% increase from the prior year.

• EBITDA was AUD 1.6 million, down 13% year-over-year due to increased investment.

• Net loss after tax was AUD 264,000, a significant improvement from the prior year's AUD 1.8 million loss, reflecting one-off legal and discontinued business impacts.

• Receipts from customers increased 14% year-over-year to AUD 8.09 million; underlying operating cash flow was positive.

• Gross margin rose to 82% year-over-year.

Outlook and guidance

• FY26 strategy focuses on finalizing the unified Single Platform, expanding supplier base, and deepening analytics capabilities.

• Marketplace expected to be the largest driver of revenue growth, especially with the new e-commerce platform launch.

• Continued investment in digital enablement, product development, and operational efficiency, with cost base expected to remain stable.

• No plans to diversify outside the pharmacy sector in the near term; international pharmacy expansion considered for the future.

• Positioned for sustained growth with a strong balance sheet and favorable market conditions.